Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.67% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 103.12M.
Overvalued
The company’s latest PE is -6.38, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.42M shares, decreasing 29.68% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 7.59K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.